This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease


Relkin, Norman R., Szabo, Paul, Adamiak, Basia, Burgut, Tuna, Monthe, Carmen, Lent, Richard W., Younkin, Steven, Younkin, Linda, Schiff, Richard, Weksler, Marc E.


Neurobiology Of Aging, Volume: 30, No.: 11, Pages.: 1728-1736

Year of Publication



Intravenous immunoglobulin (IVIg) has been proposed as a potential agent for Alzheimer’s disease (AD) immunotherapy because it contains antibodies against beta-amyloid (Abeta). We carried out an open label dose-ranging study in 8 mild AD patients in which IVIg was added to approved AD therapies for 6 months, discontinued, and then resumed for another 9 months. Infusions were generally well-tolerated. Anti-Abeta antibodies in the serum from AD patients increased in proportion to IVIg dose and had a shorter half-life than anti-hepatitis antibodies and total IgG. Plasma Abeta levels increased transiently after each infusion. Cerebrospinal fluid Abeta decreased significantly at 6 months, returned to baseline after washout and decreased again after IVIg was re-administered for an additional 9 months. Mini-mental state scores increased an average of 2.5 points after 6 months, returned to baseline during washout and remained stable during subsequent IVIg treatment. Our findings confirm and extend those obtained by Dodel et al. [Dodel, R.C., Du, Y., Depboylu, C., Hampel, H., Frolich, L., Haag, A., Hemmeter, U., Paulsen, S., Teipel, S.J., Brettschneider, S., Spottke, A., Nolker, C., Moller, H.J., Wei, X., Farlow, M., Sommer, N., Oertel, W.H., 2004. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry 75, 1472-1474] from a 6-month trial of IVIg in 5 AD patients and justify further studies of IVIg for treatment of AD.;

Bibtex Citation

@article{Relkin_2009, doi = {10.1016/j.neurobiolaging.2007.12.021}, url = {}, year = 2009, month = {nov}, publisher = {Elsevier {BV}}, volume = {30}, number = {11}, pages = {1728--1736}, author = {Norman R. Relkin and Paul Szabo and Basia Adamiak and Tuna Burgut and Carmen Monthe and Richard W. Lent and Steven Younkin and Linda Younkin and Richard Schiff and Marc E. Weksler}, title = {18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease}, journal = {Neurobiology of Aging} }


abeta, aged, aged, 80 and over, alzheimer disease, blood, cerebrospinal fluid, drug administration schedule, drug therapy, female, fluid, humans, immunoglobulins intravenous, immunologic factors, immunology, levels, male, methods, neurologic examination, peptide fragments, psychiatric status rating scales, severity of illness index, statistics nonparametric, therapeutic use, time factors

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Before and After Study

Type of Outcomes

Cognition, Other

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Intravenous Immunoglobulin IVIg